alnuctamab

{
  "id": "MLC-T-ONC-009963",
  "term": "alnuctamab",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific T-cell engager (BiTE) antibody directed against both the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, alnuctamab binds bivalently to BCMA expressed on tumor cells and monovalently to CD3 expressed on cytotoxic T-lymphocytes (CTLs). This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.",
  "synonyms": [
    "BCMA/CD3 T-cell bi-specific antibody CC-93269",
    "anti-BCMA/CD3 bispecific antibody CC-93269",
    "BCMA/CD3-directed bispecific T-cell engager antibody CC-93269",
    "BCMA x CD3 T cell-engaging antibody CC-93269",
    "bi-specific antibody CC-93269",
    "BCMAxCD3 TCB CC-93269",
    "BCMAxCD3 BiTE antibody CC-93269",
    "ALNUC"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/alnuctamab/"
}